Cleopatra Hospital CoCAI:CLHO +0.73%89 Return-on-Tangible-Equity is 14.37% as of Mar. 2026, which is 37% below its 10-year median of 22.70. GuruFocus rates CAI:CLHO with a GF Score™ of 89/100 and a GF Value™ of E£13.97 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 579 Healthcare Providers & Services companies, Cleopatra Hospital Co ranks better than 71.85% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Cleopatra Hospital Co's annualized net income for the quarter that ended in Mar. 2026 was E£472 Mil. Cleopatra Hospital Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was E£3,287 Mil. Therefore, Cleopatra Hospital Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 14.37%.
The historical rank and industry rank for Cleopatra Hospital Co's Return-on-Tangible-Equity or its related term are showing as below:
CAI:CLHO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 14.99 Med: 22.7 Max: 33.36
Current: 24.26
During the past 11 years, Cleopatra Hospital Co's highest Return-on-Tangible-Equity was 33.36%. The lowest was 14.99%. And the median was 22.70%.
CAI:CLHO's Return-on-Tangible-Equity is ranked better than 71.85% of 579
companies
in the Healthcare Providers & Services industry
Industry Median: 10.13
vs CAI:CLHO: 24.26
Cleopatra Hospital Co (CAI:CLHO) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Cleopatra Hospital Co Return-on-Tangible-Equity Related Terms
Cleopatra Hospital Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Cleopatra Hospital Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cleopatra Hospital Co Return-on-Tangible-Equity Chart
CAI:CLHO vs HCA, THC, DVA: Return-on-Tangible-Equity Comparison
For the Medical Care Facilities subindustry, Cleopatra Hospital Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cleopatra Hospital Co Return-on-Tangible-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cleopatra Hospital Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Cleopatra Hospital Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 14.37% mean?
Cleopatra Hospital Co (CAI:CLHO) has a Return-on-Tangible-Equity of 14.37% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cleopatra Hospital Co and its competitors. This is 37% below median its historical median of 22.70. Over the past decade, Cleopatra Hospital Co's Return-on-Tangible-Equity has ranged from 14.99 to 33.36. According to the industry distribution chart, Cleopatra Hospital Co ranks #163 out of 579 companies in the Healthcare Providers & Services industry, placing it in the top 28.2%.
Is Cleopatra Hospital Co's Return-on-Tangible-Equity too high?
Cleopatra Hospital Co's current Return-on-Tangible-Equity of 14.37% is 37% below median its 10-year median of 22.70. Over the past 10 years, this metric has ranged from a low of 14.99 to a high of 33.36. The Healthcare Providers & Services industry median Return-on-Tangible-Equity is 10.13. Cleopatra Hospital Co's value of 14.37% is 41.9% above this industry median. Based on the distribution chart, Cleopatra Hospital Co ranks #163 out of 579 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cleopatra Hospital Co has a GF Score™ of 89/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cleopatra Hospital Co's Return-on-Tangible-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Cleopatra Hospital Co ranks #163 out of 579 companies for Return-on-Tangible-Equity. This puts Cleopatra Hospital Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 10.13. Cleopatra Hospital Co's value of 14.37% is 41.9% above this benchmark. Historically, Cleopatra Hospital Co's own Return-on-Tangible-Equity has ranged from 14.99 to 33.36 over the past decade. While the company's 10-year median is 22.70 vs. the industry median of 10.13, Cleopatra Hospital Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Healthcare Providers & Services company?
The median Return-on-Tangible-Equity among Healthcare Providers & Services companies is 10.13, based on 579 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cleopatra Hospital Co's current Return-on-Tangible-Equity of 14.37% is 41.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Cleopatra Hospital Co and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Equity is 10.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cleopatra Hospital Co's current Return-on-Tangible-Equity is 14.37%, which is 37% below median its own 10-year median of 22.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cleopatra Hospital Co stock overvalued right now?
Based on GuruFocus' analysis, Cleopatra Hospital Co (CAI:CLHO) is currently considered Modestly Overvalued. The stock's GF Value™ is E£13.97, compared to a current price of E£16.52 — trading 18.3% above its estimated fair value. The current Return-on-Tangible-Equity is 14.37%, which is 37% below median its 10-year median of 22.70 and 41.9% above the Healthcare Providers & Services industry median of 10.13. Cleopatra Hospital Co's overall GF Score™ is 89/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Cleopatra Hospital Co (CAI:CLHO), the current Return-on-Tangible-Equity is 14.37% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cleopatra Hospital Co (CAI:CLHO) Overvalued in 2026?
Based on GuruFocus' analysis, Cleopatra Hospital Co stock appears to be overvalued.
The current stock price of E£16.52 is trading 18.3% above its estimated GF Value™ of E£13.97.
GuruFocus considers Cleopatra Hospital Co to be Modestly Overvalued.
Key valuation signals for CAI:CLHO:
Return-on-Tangible-Equity: 14.37% (37% below median its 10-year median of 22.70)
GF Value™: E£13.97 vs. price of E£16.52 (18.3% above fair value)
Industry Position: 41.9% above the Healthcare Providers & Services median (#163 of 579)
No single metric tells the full story. See the CAI:CLHO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cleopatra Hospital Co establishes a private hospital to provide modern health and medical services, in addition to medical care for inpatients. The company's segments include Cleopatra Hospital Company, Cairo Specialised Hospital, Nile Badrawy Hospital, Al Shrouk Hospital, CHG Medical Services, CHG Pharma for Pharmacy Management, CHG for Hospitals Company, Queens Hospital, ElKateb Hospital, Bedaya El Gedida Company for Medical Centers and Hospitals, CHG SKY Hospital, and Cleopatra Heaven.
89GF Score
Get the complete analysis for CAI:CLHO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:CLHO has been successfully added to your 
